Navigation Links
Zamansky & Associates LLC Investigates Affymax Inc. Over Its Recall of Omontys Due to Fatal Reactions
Date:2/26/2013

New York, New York (PRWEB) February 26, 2013

Zamansky & Associates LLC notifies all investors in Affymax Inc. (“Affymax”) that it is investigating the recall of Omontys, its anemia treatment for kidney dialysis patients due to reports of fatal reactions. On February 25, 2012, according to Bloomberg News, Affymax’s stock price fell as much as 87 percent after the recall to $2.97 per share, after it had gained 61 percent over the previous 12 months. This investigation concerns potential securities fraud or disclosure violations by Affymax, and its officers and directors, for disclosure failures relating to the fatal reactions which caused the recall.

According to the Notice issued to healthcare providers by Affymax and its marketing partner, the “use of OMONTYS may result in serious hypersensitivity reactions including anaphylaxis, which may be life-threatening or fatal,” and “to date, fatal reactions have been reported in approximately 0.02% of patients following the first dose of intravenous administration.” Reuters reported that the U.S. Food and Drug Administration on Sunday alerted healthcare providers about the recall, and said it had received 19 reports of anaphylaxis from dialysis centers in the United States.

The investigation by Zamansky & Associates LLC concerns whether Affymax knew and failed to disclose the frequency and/or severity of these reactions to Omontys, and the FDA’s response, while its stock price rose over the last year. “If Affymax’s officers and directors knew that its stock price was artificially inflated, and would likely collapse when this news was released to the market, then there was securities fraud or a disclosure law violation,” according to Jake Zamansky.

What Affymax Investors Can Do

If you are a shareholder of Affymax and would like to discuss your legal rights, you may, without obligation or cost to you, email jake (at) zamansky (dot) com or call the law firm at (212) 742-1414.

About Zamansky & Associates

Zamansky & Associates LLC is one of the leading law firms specializing in securities fraud and financial services arbitration and class action litigation. We represent both individual and institutional investors. Our practice is nationally recognized for our ability to aggressively prosecute cases and recover losses.

To learn more about Zamansky, please visit our website, http://www.zamansky.com.

Contacts

Zamansky & Associates, LLC
50 Broadway - 32nd Floor
New York, NY 10004
Jake Zamansky, 212-742-1414
jake(at)zamansky(dot)com

Read the full story at http://www.prweb.com/releases/2013/2/prweb10467316.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Michigan’s Exotic Automation & Supply to Exhibit at the 2013 Work Truck Show & Green Truck Summit
2. Parents Recommend Americord over CBR & Viacord
3. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
4. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
5. DuPont Tate & Lyle Bio Products Announces Winner of Zemea® Innovation Award
6. Industry Thought Leader to Present Transformational Opportunities for Industry Adoption of Advanced Analytics at 2013 HIMSS Annual Conference & Exhibition
7. Global Biopesticides Market Trends & Forecasts (2012 – 2017)
8. Neurovascular/Interventional Neurology Market: Global Trends & Competitive Analysis - 2017
9. Corporate Financial Planning Experts Gather at IE – Innovation Enterprise’s Financial Planning & Analysis for Pharma & Biotech Summit
10. Foot & Ankle Devices Market (2012 – 2017) By Product Type (External Fixation, Internal Fixation, Joint Replacement, Prosthesis, Bracing) - Global Trends & Competitive Analysis
11. The Leukemia & Lymphoma Society: Impacting Blood Cancers and Beyond
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Foresight Institute, ... and other transformative technologies, announced the winners for the 2017 Foresight Institute Feynman ... Theory in nanotechnology/molecular manufacturing. , Established in 1993 and named in honor of ...
(Date:9/19/2017)... ... September 19, 2017 , ... VetStem Biopharma ’s CEO and founder, Dr. Bob ... in Riordan’s new book "Stem Cell Therapy: A Rising Tide". Dr. Harman and Dr. ... They bonded over an interest in the potential of stem cell therapy and a fast ...
(Date:9/19/2017)... ... 2017 , ... Molecular Devices, LLC, a leader in protein ... the CloneSelect™ Single-Cell Printer™ in North America. This novel system utilizes sophisticated ... documentation of monoclonality for use in cell line development. , Clonal cell ...
(Date:9/18/2017)... MONTREAL , Sept. 18, 2017   Montrium , a ... announced an exciting new partnership with a groundbreaking non-profit research organization, ... ... for MDMA-assisted psychotherapy studies for PTSD ... FDA has recently granted Breakthrough Therapy Designation to MDMA for the ...
Breaking Biology Technology:
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
Breaking Biology News(10 mins):